


Application Ser. No.: 10/808,889  
 Filing Date: March 25, 2004  
 Examiner: Lee, Susannah E.

Amendment Pursuant to 37 C.F.R. § 1.121(c)

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound of formula (I)



wherein

A is aryl or heteroaryl;

R<sub>1</sub> is one or more groups selected from:

alkyl optionally substituted by one or more alkoxy, heteroalkyl, aryl, acyl, acyl derivative, halogen, amino, aminoalkyl, aminoalkylamine, hydroxy, hydroxyalkoxy, alkyl, arylalkyl, arylamine or aryloxy;

alkoxy optionally substituted by one or more alkyl, heteroalkyl, aryl, heteroaryl, alkylalkyl, hydroxyalkyl, amide, amino, acyl, acyl derivative, arylalkyl, perfluoroalkoxy, or alkylthio optionally substituted by amide, perfluoroalkylthio, amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

aryl or heteroaryl optionally substituted by one or more similar or different groups selected from alkyl, alkoxy, nitro, cyano, acyl derivative, perfluoroalkoxy, perfluoroalkyl, heteroaryl, aryloxy, halogen, hydroxyalkyl, amino, mono or dialkylamine, heterocyclylamine, arylamine, heteroarylamine, heterocycloalkyl, perfluoroalkylthio, or alkylthio optionally substituted by amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

halogen;

NH<sub>2</sub>;

Application Ser. No.: 10/808,889  
 Filing Date: March 25, 2004  
 Examiner: Lee, Susannah E.

NH-alkyl or NH-cycloalkyl optionally substituted by acyl, acyl derivative, hydroxy, amino, alkoxy, heterocycl<sup>1</sup> chosen from substituted or unsubstituted tetrahydrofuryl, tetrahydropyran<sup>1</sup>, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or azepanyl, or aryl; or 1-imidazolyl; or  
 $\text{SO}_2\text{Me}$ ;

$R_2$  is:

-CO-alkyl or -CO-cycloalkyl wherein said -CO-alkyl or -CO-cycloalkyl is optionally substituted by one or more amino, acyl, acyl derivative, alkoxy, aryl, OH, aminoalkyl, aminoalkylamino, hydroxyalkoxy, alkyl, heteroalkyl, arylalkyl, arylamino or aryloxy;

-CO-aralkyl optionally substituted by one or more similar or different groups selected from alkoxy, halogen, amino, acyl, acyl derivative, alkyl, hydroxyalkyl, mono or dialkylamino, heteroalkylamino, arylamino, heteroarylamino, heteroaryl, nitro, heterocycloalkyl, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or alkylthio optionally substituted by amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

-CO-aryl optionally substituted by one or more similar or different groups selected from halogen, alkoxy, alkyl, hydroxyalkyl, alkylthio, amino, mono or dialkylamino, heterocyclamino, arylamino, heteroarylamino, heteroaryl, nitro, heterocycloalkyl, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or acyl;

-CO-alkoxy optionally substituted by aryl, amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

-CO-amino, -CO-NHR<sub>3</sub>, -CO-NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl heterocycl selected from pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkyl, piperidinylalkyl, tetrahydropyran<sup>1</sup>alkyl or morpholinylalkyl, alkylheterocycloalkyl selected from 4-alkylpiperazinylalkyl or N-alkyl-pyrrolidinylalkyl, aryl, aralkyl, or together form an alkylene chain optionally containing one to 4 heteroatoms selected from azetidine, pyrrolidine or piperidine, and optionally

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

substituted by one or more amino, aminoalkyl, aminoalkylamino, hydroxy, alkoxy, hydroxyalkoxy, hydroxyalkylamino, halogen, acyl, acyl derivative, alkyl, heteroalkyl, arylalkyl, arylamino, aryloxy or aryl; or

aryl or aralkyl optionally substituted by one or more similar or different groups selected from heterocycloalkyl heterocyclyl selected from morpholinyl or alkyl piperazinyl, alkyl, aryl, alkoxy, amino, fluoroalkyl, acyl derivative, halogen, hydroxyalkyl, mono or dialkylamino, heterocyclylamino, arylamino, heteroarylamine, heteroaryl selected from oxadiazolyl, nitro, heterocycloalkyl, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or alkylthio optionally substituted by amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

wherein when A is phenyl and R<sub>1</sub> is NH<sub>2</sub>, NH-alkyl, NH-cycloalkyl or 1-imidazolyl, said phenyl is substituted at the 4-position with said R<sub>1</sub>; and when A is phenyl and R<sub>1</sub> is SO<sub>3</sub>Me said phenyl is substituted at the 3-position with said R<sub>1</sub>;

with the proviso that when R<sub>2</sub> is -CO-alkoxy, R<sub>1</sub> is NH-cycloalkyl, or a pharmaceutically acceptable salt or a prodrug thereof.

2. (original) The compound according to claim 1 wherein acyl is a carboxylic acid or a sulfonic acid and acyl derivative is an alkyl or carbamoyl ester.

3. (currently amended) A compound according to claim 2 wherein:

A is aryl or heteroaryl;

R<sub>1</sub> is one or more groups selected from:

alkyl optionally substituted by alkoxy, heteroalkyl, aryl, acyl, acyl derivative, or halogen;

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

alkoxy optionally substituted by alkyl, heteroalkyl, aryl, heteroaryl,  
alkoxyalkyl, hydroxyalkyl, amide or perfluoroalkoxy, or alkylthio  
optionally substituted by an amide or perfluoroalkylthio;  
aryl or heteroaryl optionally substituted by one or more alkyl, alkoxy,  
nitro, cyano, acyl derivative, perfluoroalkoxy, perfluoroalkyl, heteroaryl or  
aryloxy;  
halogen;

NH<sub>2</sub>;

NH-alkyl or NH-cycloalkyl optionally substituted by acyl, acyl derivative, hydroxy, amino; alkoxy, heterocyclyl chosen from substituted or unsubstituted tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or azepanyl, or aryl; or 1-imidazolyl; or

SO<sub>2</sub>Me;

R<sub>2</sub> is:

-CO-alkyl or -CO-cycloalkyl wherein said -CO-alkyl or -CO-cycloalkyl is optionally substituted by amino, acyl, acyl derivative, alkoxy, aryl or OH;  
-CO-aralkyl optionally substituted by alkoxy, halogen, amino, acyl or acyl derivative;  
-CO-aryl optionally substituted by halogen, alkoxy, alkyl, hydroxyalkyl, alkylthio, amino, mono or dialkylamino, nitro, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or acyl;  
-CO-alkoxy optionally substituted by aryl;  
-CO-amino, -CO-NHR<sub>3</sub>, -CO-NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl heterocyclyl selected from

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkyl, piperidinylalkyl,  
tetrahydropyranylalkyl or morpholinylalkyl, alkylheterocycloalkyl selected  
from 4-alkylpiperazinylalkyl or N-alkyl-pyrrolidinylalkyl, aryl, aralkyl or  
together form an alkylene chain optionally containing one to 4 heteroatoms  
selected from azetidine, pyrrolidine or piperidine; or  
aryl or aralkyl optionally substituted by heterocycloalkyl heterocyclyl  
selected from morpholinyl or alkyl piperazinyl, alkyl, aryl, alkoxy, amino,  
fluororoalkyl, acyl derivative, or halogen.

4. (currently amended) The compound according to claim 3 wherein A is phenyl, thiophenyl, isoxazolyl, oxazolyl, pyrazolyl, furanyl or pyridinyl.

5. (canceled).

6. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R<sub>1</sub> is NH-cycloalkyl and R<sub>2</sub> is -CO-alkoxy.

7. (original) The compound according to claim 6 wherein the compound is methyl-5-(4-cyclopentylaminophenylsulfonyloxy) benzimidazole-2-carbamate.

8. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R<sub>1</sub> is 1-imidazolyl or cyclopentylamino and R<sub>2</sub> is -CO-alkyl optionally substituted by amino, acyl, acyl derivative, alkoxy, aryl or OH.

9. (original) The compound according to claim 8 wherein the compound is selected from the group consisting of:

N-[5-(4-imidazol-1-yl-benzenesulfonyloxy)-1H-benzimidazol-2-yl]-succinamic acid methyl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

N-[5-(4-cyclopentylamino-benzenesulfonyloxy)-1H-benzimidazol-2-yl]-succinamic acid methyl ester,

4-[5-(4-cyclopentylamino-benzenesulfonyloxy)-1H-benzimidazol-2-ylcarbamoyl]-butyric acid methyl ester, and

4-cyclopentylamino-benzenesulfonic acid 2-(2-methoxy-acetylamino)-1H-benzimidazol-5-yl ester.

10. (currently amended) The compound according to claim 5 claim 4 wherein R<sub>1</sub> is alkoxy, 1-imidazolyl, or NH-alkyl or NH-cycloalkyl optionally substituted by acyl, acyl derivative, hydroxy, amino, alkoxy, heterocyclyl chosen from substituted or unsubstituted tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or azepanyl or aryl and R<sub>2</sub> is -CO-amino, -CO-NHR<sub>3</sub>, -CO-NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are selected independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl heterocyclyl selected from pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkyl, piperidinylalkyl, tetrahydropyranylalkyl or morpholinylalkyl, alkylheterocycloalkyl selected from 4-alkylpiperazinylalkyl or N-alkyl-pyrrolidinylalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms selected from azetidine, pyrrolidine or piperidine.

11. (currently amended) The compound according to claim 10 selected from the group consisting of:

N-[5-(4-[imidazolyl]-phenylsulfonyloxy)-1H-benzimidazole-2-yl]-methylurea,

N-[5-(4-cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-methylurea,

N-[5-(4-cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-dimethylurea,

4-cyclopentylamino-benzenesulfonic acid 2-(3-isopropyl-ureido)-1H-benzimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-(3-butyl-ureido)-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-methoxy-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-methoxy-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-chloro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-fluoro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-chloro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-isobutyl-ureido)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-dimethylamino-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-ethyl-ureido)-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-dimethylamino-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-tert-butyl-ureido)-1H-benzoimidazol-5-yl ester,

4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-(3-methyl-ureido)-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-(3-phenyl-ureido)-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(3-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-hydroxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(4-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-chloro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-fluoro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[(azetidine-1-carbonyl)-amino]-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-(3-benzyl-ureido)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-phenyl-ureido)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-hydroxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-chloro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-fluoro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-[(azetidine-1-carbonyl)-amino]-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-(3-benzyl-ureido)-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-hydroxy-propyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-[3-(1,1-dimethyl-propyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-hydroxy-butyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-hydroxy-1-methyl-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(2-hydroxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(3-hydroxy-propyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(4-hydroxy-butyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(2-methoxy-1-methyl-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,  
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-(3-ethyl-ureido)-1H-benzoimidazol-5-yl ester.  
4-(2-methoxy-ethylamino)-benzenesulfonic acid 2-[3-(2-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susanah E.

4-(2-hydroxy-1-methyl-ethylamino)-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H- benzoimidazol-5-yl ester,  
4-(2-hydroxy-1-methyl-ethylamino)-benzenesulfonic acid 2-[3-(2- ethyl)- ureido]-1H- benzoimidazol-5-yl ester,  
~~4-benzyleoxy benzenesulfonic acid 2-[3-(2-methoxy-ethyl)- ureido]-1H- benzoimidazol-5-yl ester,~~  
4-(2-morpholin-4-yl-ethylamino)-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)- ureido]-1H- benzoimidazol-5-yl ester,  
4-[(piperidin-4-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)- ureido]-1H- benzoimidazol-5-yl ester, and  
4-(2-hydroxy-3-methoxy-propylamino)-benzenesulfonic acid 2-[3-(2-hydroxy-3-methoxy-propyl)-ureido]-3H-benzoimidazol-5-yl ester.

12. (currently amended) The compound according to claim 5 claim 4 wherein R<sub>2</sub> is -CO-cycloalkyl.

13. (original) The compound according to claim 12 wherein R<sub>2</sub> is -CO-cyclopropyl.

14. (currently amended) The compound according to claim 13 selected from the group consisting of:

4-benzylamino-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H- benzoimidazol-5-yl ester,  
4-methylamino-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H- benzoimidazol-5-yl ester,  
4-(2-hydroxy-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H- benzoimidazol-5-yl ester,  
4-(3-hydroxy-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H- benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

4-(4-hydroxy-butylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-methoxy-1-methyl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-pyrrolidin-1-yl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(1-hydroxymethyl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-hydroxy-1-methyl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-piperidin-1-yl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(3-pyrrolidin-1-yl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(3-hydroxy-2,2-dimethyl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-[3-(4-methyl-piperazin-1-yl)-propylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-methoxy-benzylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-diethylamino-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(1S-hydroxymethyl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-morpholin-4-yl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(1-aza-bicyclo[2.2.2]oct-3-ylamino)-benzenesulfonic acid 2-(cyclopropane-carbonyl-amino)-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

4-(2R-carbamoyl-pyrrolidin-1-yl) benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-piperazin-1-yl-ethylamino)-benzene-sulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-carbamoyl-cyclohexylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-(2-acetylamino-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-[2-(2-amino-ethylamino)-ethylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-[2-(1H-imidazol-4-yl)-ethylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-[(pyridin-2-ylmethyl)-amino]-benzenesulfonic acid 2-(cyclopropane-carbonyl-amino)-1H-benzoimidazol-5-yl ester,  
4-cyclobutylamino-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester, and  
4-[2-(2-hydroxy-ethoxy)-ethylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester.

15. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R<sub>1</sub> is cyclopentylamino and R<sub>2</sub> is aryl or aralkyl optionally substituted by heterocycloalkyl heterocycl selected from morpholinyl or methylpiperazinyl, alkyl, aryl, alkoxy, amino, fluoroalkyl fluoroalkyl, acyl derivative, or halogen.

16. (original) The compound according to claim 15 selected from the group consisting of:

4-cyclopentylamino-benzenesulfonic acid 2-(3,4-dimethoxy-phenylamino)-1H-benzoimidazol-5-yl ester,  
4-cyclopentylamino-benzenesulfonic acid 2 -phenylamino-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889  
Filing Date: March 25, 2004  
Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-(4-morpholin-4-yl-phenylamino)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3,5-dimethyl-phenylamino)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(4-methoxy-phenylamino)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(4-dimethylamino-phenylamino)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-methoxy-5-trifluoromethyl-phenylamino)-1H-benzoimidazol-5-yl ester,

3-[5-(4-cyclopentylamino-benzenesulfonyloxy)-1H-benzoimidazol-2-ylamino]-benzoic acid ethyl ester, and

4-cyclopentylamino-benzenesulfonic acid 2-[(4-(4-methyl-piperazin-1-yl)-phenylamino)-1H-benzoimidazol-5-yl ester.

17. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 and one or more pharmaceutically acceptable adjuvants or diluents.

18. (currently amended) A method of treating a patient for cancer selected from the group consisting of breast, ovarian, bladder, esophageal, lung and lymphoma comprising administering to said patient a therapeutically effective amount of a compound of formula (I) according to claim 1.